Jay Parrish

Chairman and CEO

2021

Developing treatments to address the genetic roots of mitochondrial dysfunction

Venture Partner

2016

We’re catalyzing discoveries that prevent, detect, and cure disease

Chairman of the Board

2020

Series A company focused on small molecule solutions to several types of kidney stones (oxalate and cystine) and high-recurrent patient populations within. Formerly known as GyanRx.

Co-Founder and Board Member

2022

Strategic Advisor

2023

Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues towards the treatment of human disease. https://magnetbio.com

Co-Founder and Member Board Of Directors

2019

Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases

Strategic Advisor

2022

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible

Board Observer

2021

Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination

Member Board Of Directors

2021

Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease.

Strategic Advisor

2021 - 2024

Sold to Biogen for $1.8B ($1.15B upfront and $650M in milestones)